Association of British Clinical Diabetologists

Dapagliflozin Nationwide Audit

 
Home Live ABCD nationwide audits of new therapies All ABCD nationwide audits Future audits of new therapies ABCD worldwide audits
     

Above - from the first oral presentation of data from the audit at the ABCD autumn meeting, November 6, 2015. The patients in the audit are much more poorly controlled and with much higher BMI than in the clinical trials with dapagliflozin - click to enlarge

 

Above: from the first poster from the audit at the ABCD Autumn meeting, November 6, 2015. It seems that dapagliflozin has a statistically and clinically significant response on ALT reduction in Type 2 diabetes patients with a high baseline ALT≥30U/l - click to enlarge

 

ABCD nationwide and worldwide dapagliflozin audit

Papers, abstracts, presentations, posters and webcasts emanating from the audit

 

Webcasts

Webcast of ABCD research fellow Dr Mahender Yadagiri presenting ABCD dapagliflozin audit poster at EASD, Munich, 13 September 2016

Effect of dapagliflozin on HbA1c and weight after its addition to various combinations of other diabetes medications

 

Published papers  

Ken Yan Thong, Mahender Yadagiri, Dennis Joseph Barnes,
David Stuart Morris, Tahseen Ahmad Chowdhury, Ling Ling Chuah, Anthony Michael Robinson, Stephen Charles Bain, Karen Ann Adamson, Robert Elford John Ryder, ABCD Nationwide Dapagliflozin Audit contributors: Clinical risk factors predicting genital fungal infections with sodium–glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit

Primary Care Diabetes pcd.2017.06.004
Full paper (ABCD members and audit contributors only):
Primary Care Diabetes pcd.2017.06.004

 

Slides from presentations

ABCD Autumn meeting, London, November 6 2015
DUK Professional Conference, Glasgow, March 4 2016

ADA, San Diego, June 11 2017

 

Abstracts
ABCD Autumn Meeting, London, 2015a: M Yadagiri, P Sen Gupta, ML Cull, R Peter, P De, A Robinson, KA Adamson, REJ Ryder on behalf of the ABCD nationwide dapagliflozin audit contributors. HbA1c, weight, body mass index (BMI) and systolic blood pressure changes in the ABCD nationwide dapagliflozin audit. Oral presentation: Abstract 2
ABCD Autumn Meeting, London, 2015b: M Yadagiri, P Sen Gupta, SC Bain, A Robinson, M Phyactou, A Kennedy, KA Adamson, REJ Ryder on behalf of the ABCD nationwide dapagliflozin audit contributors. Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase and Type 2 diabetes?: the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit. Poster presentation: Abstract 10

DUK, Glasgow, 2016a: – M Yadagiri, P Sen Gupta, ML Cull, J Eyles, A Robinson, L Oguntolu, K Imtiaz, K Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin Audit Contributors. HbA1c,weight,body mass index(BMI) and systolic blood pressure changes in the ABCD nationwide audit(poster presentation:P432).

DUK, Glasgow, 2016b: – M Yadagiri, P Sen Gupta, JW Stephens, A Robinson, M Phylactou, A Kennedy, J Clark, J Wilding, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin Audit Contributors. Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase and Type 2 diabetes? The Association of British Clinical Diabetologists(ABCD) nationwide dapagliflozin audit(oral presentation:A73/P427).

ABCD Spring Meeting 2016, Manchester - K.Y. Thong, M. Yadagiri, P. Sen Gupta, P. Winocour, M. Joshi, J. Wilding, JW Stephens, SC Bain, A. Robinson, IW Gallen, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin audit contributors. The glycaemic response to dapagliflozin according to intensity of background diabetes treatment or duration of Type 2 Diabetes: the Association of British Clinical Diabetologists Nationwide Dapagliflozin audit. Poster presentation : Abstract 3

ADA New Orleans, 2016a - M. Yadagiri, P. Sen Gupta, ML Cull, D. Price, V Oguntolu, K Imtiaz, D Barnes, A Nugent, A Robinson, IW Gallen, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin audit contributors. Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase(ALT) and Type 2 diabetes? The Association of British Diabetologists Nationwide Dapagliflozin audit. Poster presentation: 1123-P

ADA New Orleans, 2016b – M. Yadagiri, P. Sen Gupta, A. Kennedy, T. Pang, J. Clark, H. Pathan, P.C. Johnston, R. Chudleigh, A. Robinson, IW Gallen, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin audit contributors. HbA1c,weight, body mass index(BMI) and systolic blood pressure response to dapagliflozin: The Association of British Clinical Diabetologists Nationwide Dapagliflozin audit. Poster presentation: 1164-P

ADA New Orleans, 2016c - K.Y. Thong, M. Yadagiri, P. Sen Gupta, P. Winocour, M. Joshi, J. Wilding, JW Stephens, SC Bain, A. Robinson, IW Gallen, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin audit contributors. The glycaemic response to dapagliflozin according to intensity of background diabetes treatment or duration of Type 2 Diabetes: the Association of British Clinical Diabetologists Nationwide Dapagliflozin audit. Poster presentation: 1170-P

EASD Munich, 2016 - M Yadagiri, P Sen Gupta, T Pang, L Balmuri, T Robinson, S Bain, IW Gallen, KA Adamson, REJ Ryder on behalf of ABCD nationwide dapagliflozin audit contributors. Effect of dapagliflozin on HbA1c and weight after its addition to various combinations of other diabetes medications: Association of British Clinical Diabetologists(ABCD) nationwide dapagliflozin audit –Diabetologia(2016) Vol 59 Supplement 1: S581- Abstract 712

DUK Manchester, 2017 - M Yadagiri, P Sen Gupta, A Kennedy, T Pang, L Balmuri, T Robinson, S Bain, IW Gallen, KA Adamson, REJ Ryder on behalf of ABCD nationwide dapagliflozin audit contributors. The effect of dapagliflozin on HbA1c and weight after its addition to commonly prescribed dual combination diabetes medication regimes in people with Type 2 diabetes in a real-world UK setting: the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit – Diabetic Medicine volume 34 (Supplement S1, 36-194) - Poster 519

ADA San Diago, 2017a - M Yadagiri, S C Bain, T Robinson, JPH Wilding, T Pang, B McGowan, P Winocour, V Oguntolu, J Clark, H Partridge, IW Gallen, KA Adamson, REJ Ryder, ABCD nationwide dapagliflozin audit contributors. Dapagliflozin in Renal Impairment : the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit – Diabetes June 2017 Volume 66 (Supplement 1, A45) : Oral 172-OR

ADA San Diego,2017b - KY Thong, M Yadagiri, P Tong, D Barnes, D Morris, T Chowdhury, LL Chuah, M Cohen, A Kennedy, T Robinson, SC Bain, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin audit contributors. Lack of risk factors predicting the development of genital mycotic infections among patients treated with dapagliflozin : the Association of British Clinical Diabetologists Nationwide Dapagliflozin audit. Poster presentation: 1287-P

 

 

 

Posters
ABCD London, Autumn 2015

DUK Professional Conference, Glasgow, March 4 2016a

DUK Professional Conference, Glasgow, March 4 2016b

ABCD Manchester, Spring 2016
ADA New Orleans, June 2016a
ADA New Orleans, June 2016b
ADA New Orleans, June 2016c

EASD Munich, 2016

DUK Professional Conference, Manchester, March 2017

ADA San Diego, June 11 2017b

 

 

 

   ABCD dapaglflozin audit homepage

 Register for the dapagliflozin audit

Register simulateously for both dapagliflozin and exenatide qw audits

Access the on-line tool
(you need to be on N3)

Access the worldwide on-line tool
(Northern Ireland)

Dapagliflozin audit objectives

Order preprinted data entry forms

Download first visit data entry form

Download follow up visit data entry form

Papers, abstracts, presentations, posters from the audit

Further information- contact us

Main ABCD homepage

     

The ABCD nationwide dapagliflozin audit is an independent audit supported by an unrestricted grant from Astra Zeneca

Working to support high quality diabetes care in the UK